- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Panel Discussion: Defining Quality in Oncology: Is There a Common Ground?
Although there have been some accusations of "cookbook medicine" with regards to measurement guidelines, panelists Dennis Scanlon, PhD, Jess DeMartino, PhD, Phyllis Torda, and Laura Long, MD, do see progress to remedy the situation and make guidelines more effective.
%jwplayer%
Although there have been some accusations of “cookbook medicine” with regards to measurement guidelines, panelists Dennis Scanlon, PhD, Jess DeMartino, PhD, Phyllis Torda, and Laura Long, MD, do see progress to remedy the situation and make guidelines more effective.
Part of the problem is in the measurement itself, according to Dr Scanlon, who recommends going back to the reason why the industry measures in the first place, such as for accountability, quality improvement, surveillance and payment purposes.
Dr Long added that guidelines should not just be for evidence-based care or efficacy but what is important to patients. The National Comprehensive Cancer Network, where Dr DeMartino works, aims to educate patients with their own set of guidelines that include glossary terms to explain concepts like deductibles and co-pays.
Ms Torda added that active promotion of patient involvement is becoming more common and patients are being engaged in 3 ways: directly in the delivery of their care; through advisory boards within practices; and with advocacy on the policy level.
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
Trastuzumab Deruxtecan Receives FDA Approval for HER2-Positive Solid Tumors
April 5th 2024FDA granted accelerated approval to trastuzumab deruxtecan-nxki for adult patients with unresectable or metastatic HER2-positive solid tumors who received prior systemic treatment and have no satisfactory alternative treatment options.
Read More
